Zidovudine-induced nail hyper-pigmentation in 45-year-old women prescribed for HIV/tuberculosis co-infection

Vishal R Tandon; Shamiya Sadiq; Vijay Khajuria; Annil Mahajan; Sudhaa Sharma; Zahid Gillani

doi:10.4103/0976-7800.179176

Zidovudine-induced nail hyper-pigmentation in 45-year-old women prescribed for HIV/tuberculosis co-infection

J Midlife Health. 2016 Jan-Mar;7(1):38-40. doi: 10.4103/0976-7800.179176.

Authors

Vishal R Tandon¹, Shamiya Sadiq², Vijay Khajuria², Annil Mahajan³, Sudhaa Sharma⁴, Zahid Gillani²

Affiliations

¹ Department of Pharmacology and Therapeutics, Government Medical College, Jammu City, Jammu and Kashmir, India.
² Department of Pharmacology, Government Medical College, Jammu City, Jammu and Kashmir, India.
³ Department of Internal Medicine, Government Medical College, Jammu City, Jammu and Kashmir, India.
⁴ Department of Obstetrics and Gynecology, Government Medical College, Jammu City, Jammu and Kashmir, India.

Abstract

Zidovudine is an important component of first-line antiretroviral treatment regimens used to manage HIV and tuberculosis (TB) co-infection. Nail pigmentation is documented both in adult as well as pediatric HIV patients, but to the best of our knowledge, it has not been reported in 45-year-old women of HIV/TB co-infection. Such an adverse drugs reactions (ADR), although is harmless and reversible, psychological aspects of such ADR may be immense to the extent that it can negatively affect the compliance and result in therapeutic failure. Thus, it is worth reporting.

Keywords: Adverse drugs reactions; HIV and tuberculosis co-infection; Zidovudine; nail hyper-pigmentation.

Publication types

Case Reports